Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
